Expert Ratings for Bicycle Therapeutics
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Bicycle Therapeutics Q1 EPS $(0.93) Down From $(0.73) YoY
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.93) per share. This is a 27.4 percent decrease over losses of $(0.73) per share from the same period last year.
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00.
Shares of Bicycle Therapeutics are trading down 5.7% over the last 24 hours, at $23.48 per share.
Where Bicycle Therapeutics Stands With Analysts
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $75
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $85 to $75.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.
Bicycle Therapeutics To Present Interim BT8009 Phase I Clinical Trial Results At 2022 AACR Annual Meeting
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
- Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET
Bicycle Therapeutics plc
Bicycle Therapeutics’s Return On Capital Employed Overview
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a loss of $18.04 million.
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: